The use of monoclonal antibody therapies is exploding in areas such as immunology, rheumatology and gastroenterology. Although these drugs are currently prescribed only by specialists, GPs may be called on to recognise and manage adverse events following their administration.
Biological agents, encompassing monoclonal antibodies (MAbs), fusion proteins and cytokines, have become ubiquitous treatments in modern medical practice.1 Most medical specialties have at least one biological therapy in use or in the pipeline. With the increasing use of therapeutic MAbs, more patients are experiencing adverse effects, including hypersensitivity reactions. GPs must be able to recognise the adverse effects of MAbs and refer patients for review if required.
Picture credit: © Burger/Phanie/SPL